US Broker Ratings

MBX Biosciences, Inc. (MBX)

⚠️ No article content returned.

..

Kamada Ltd. (KMDA) Stock Analysis: A Healthcare Gem with 55.71% Potential Upside

Kamada Ltd. (NASDAQ: KMDA), an Israel-based healthcare company specializing in plasma-derived protein therapeutics, is garnering attention from investors due to its robust revenue growth and promising analyst ratings. With a..

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Clinical-Stage Biotech with a 49.90% Upside Potential

Rapport Therapeutics, Inc. (RAPP), a clinical-stage biotechnology firm headquartered in Boston, Massachusetts, is gaining traction among investors due to its promising pipeline and significant potential upside. Operating within the healthcare..

AngioDynamics, Inc. (ANGO) Stock Analysis: Potential 30% Upside Amid Strong Buy Ratings

AngioDynamics, Inc. (NASDAQ: ANGO) is garnering attention among healthcare investors as it stands poised for potential growth, driven by strategic advancements in medical technology. With a market capitalization of $635.28..

Prothena Corporation plc (PRTA) Stock Analysis: Unveiling a 153% Upside Potential Amidst Biotech Challenges

Prothena Corporation plc (NASDAQ: PRTA), a biotechnology firm headquartered in Dublin, Ireland, is capturing the attention of investors with an impressive potential upside of 152.96%. Specializing in the development of..

Celcuity Inc. (CELC) Stock Analysis: Unpacking an 89.32% Potential Upside in Biotech

Investors looking for high potential in the biotechnology sector should take note of Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotech company with a strong focus on developing targeted therapies for..

Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A 58.6% Potential Upside Beckons Biotech Investors

Oruka Therapeutics, Inc. (NASDAQ: ORKA) is capturing the attention of savvy investors in the biotechnology sector with its groundbreaking work in monoclonal antibody therapeutics. As a clinical-stage biopharmaceutical company, Oruka..

Oric Pharmaceuticals (ORIC) Stock Analysis: A 60% Upside Potential with Strong Buy Ratings in Biotech

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) is capturing investor attention with its promising potential for substantial upside. As a clinical-stage biopharmaceutical firm, Oric focuses on developing innovative therapies to tackle cancer..

Orthofix Medical Inc. (OFIX) Stock Analysis: Exploring a 50% Upside Potential

Orthofix Medical Inc. (NASDAQ: OFIX) is positioning itself as a compelling opportunity within the healthcare sector, specifically in the medical devices industry. With a market capitalization of approximately $351.93 million,..

Abivax SA (ABVX) Stock Analysis: Exploring a 54% Potential Upside in the Biotech Sector

Abivax SA (ABVX), a clinical-stage biotechnology company headquartered in Paris, France, is capturing the attention of investors with a substantial potential upside of 54.22%. Specializing in the development of therapeutics..

Definitive Healthcare Corp. (DH) Stock Analysis: Unveiling a 98% Upside Potential Despite Current Challenges

Definitive Healthcare Corp. (NASDAQ: DH), a key player in the healthcare information services sector, presents a captivating case for investors willing to delve into a company with significant upside potential..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Tapping into a 24.82% Upside Potential

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is making waves in the healthcare sector, especially within the niche of specialty and generic drug manufacturing. With a market capitalization of $4.33 billion, this..

COMPASS Pathways Plc (CMPS) Stock Analysis: Strong Buy Ratings and 58% Upside Potential

COMPASS Pathways Plc (CMPS) is making waves in the healthcare sector with its innovative approach to mental health treatment. As a biotechnology company headquartered in London, COMPASS Pathways is pioneering..

Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 486% Potential Upside in the Biotech Sector

Investors with an eye on the biotechnology sector may find Upstream Bio, Inc. (NASDAQ: UPB) an intriguing prospect, especially given its substantial potential upside of 486.49%. Despite its current challenges,..

Standard BioTools Inc. (LAB) Stock Analysis: Potential Upside with a Target Price of $1.35

Standard BioTools Inc. (NASDAQ: LAB), a player in the healthcare sector with a focus on medical devices, is drawing attention from investors with a noteworthy potential upside of approximately 84.93%,..

Humacyte, Inc. (HUMA) Stock Analysis: Unpacking a 221.68% Potential Upside in the Biotech Arena

Investors navigating the volatile waters of the biotechnology sector may want to give Humacyte, Inc. (NASDAQ: HUMA) a closer look. With a promising potential upside of 221.68%, this small-cap company..

Emergent BioSolutions Inc. (EBS) Stock Analysis: Unpacking a 56.7% Potential Upside

Emergent BioSolutions Inc. (NYSE: EBS), a prominent player in the healthcare sector, is capturing investor attention with its significant potential upside of 56.7%. Specializing in preparedness and response solutions for..

RxSight, Inc. (RXST) Stock Analysis: Evaluating the 46% Potential Upside in Medical Device Innovation

RxSight, Inc. (RXST), a pioneering player in the medical devices sector, offers investors a unique proposition with its innovative approach to cataract surgery solutions. Specializing in light adjustable intraocular lenses..

Stoke Therapeutics, Inc. (STOK) Investor Outlook: Exploring a 60.60% Potential Upside in Biotechnology

Stoke Therapeutics, Inc. (NASDAQ: STOK) is making waves in the biotechnology sector with its innovative approach to developing treatments for severe genetic diseases. Based in Bedford, Massachusetts, this U.S.-based company..

AbCellera Biologics Inc. (ABCL) Stock Analysis: A Biotech Gem with a 34% Upside Potential

AbCellera Biologics Inc. (NASDAQ: ABCL) continues to capture investor attention due to its promising potential in the biotechnology sector. Based in Vancouver, Canada, this innovative company is carving a niche..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds